| | GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference. | Conference Details: | | | | Presentation and Q&A | | | Date: | Monday, January 8, 2024 | | Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | | Location: | Westin St. Francis Hotel in San Francisco, California | | Moderator: | Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research | | Novavax participants: | John C. Jacobs, President and Chief Executive Officer | | | | | | Conference | | | Event: | Investor Meetings | | Date: | Monday, January 8, 2024 | Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company’s website at ir.novavax.com for 30 days from the date of the conference. About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax’s patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com Media
Ali Chartan
240-720-7804
media@novavax.com  View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-42nd-annual-jp-morgan-healthcare-conference-302024821.html
SOURCE NOVAVAX, INC | |
